跳至主要内容
临床试验/NCT05522374
NCT05522374招募中不适用

TIRCON International NBIA (Neurodegeneration Associated With Brain Iron Accumulation) Patient Registry and Natural History Study

LMU Klinikum9 个研究点 分布在 8 个国家目标入组 2,000 人开始时间: 2012年6月14日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
2,000
试验地点
9
主要终点
Change in Score on the Barry-Albright Dystonia (BAD) Scale

研究概览

简要总结

TIRCON-reg aims to

  • continue the provision of a global registry and natural history study for NBIA disorders
  • harmonize and cover existing national and single site registries
  • enable participation of countries and single sites that so far have no access to an NBIA registry
  • join forces in order to recruit sufficient numbers of patients
  • define the natural history of NBIA disorders
  • define the most appropriate outcome measures
  • inform the design and facilitate the conduction of clinical trials

详细描述

The TIRCON international patient registry and natural history study for patients with Neurodegeneration Associated with Brain Iron Accumulation (NBIA) was initiated and funded for the first four years by TIRCON (Treat Iron-Related Childhood-Onset Neurodegeneration), an international consortium supported by the European Union between November 1st 2011 and October 31st, 2015. Since then, the registry has been sustained through donations form Patient Organizations and industry.

Harmonization of existing data has been performed by establishing and applying matching and transformation rules. The web-based registry is now fully functional for a critically needed natural history study of all NBIA subtypes. A focus has been set on scores that are most appropriate to reflect stage and progression of disease, e.g. the Barry Albright Dystonia scale, the Patient´s Global Impression of Improvement (PGII), the Unified Parkinson Disease Rating Scale (UPDRS; parts I-III and VI) and quality-of-life scores. The natural history data are collected yearly, or in rapidly progressing cases every six months, if applicable. Patients who present to one of our centers are eligible after informed consent to participate.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • suspected or confirmed NBIA
  • willingness to participate

排除标准

  • unwillingness to participate

结局指标

主要结局

Change in Score on the Barry-Albright Dystonia (BAD) Scale

时间窗: The individual participants are followed with annual assessments over a long time period (up to 30 years) or until discontinuation or death.

The Barry-Albright Dystonia Scale is an instrument for rating the severity of dystonia in eight body regions. The individual scores are summed to provide a total score that ranges from 0 to 32; the higher the score, the more severe the dystonia. Patients with dystonia are assessed for the change in total BAD score over time since Baseline.

Change in Score on Unified Parkinson's Disease Rating (UPDRS) Scale, Part I-III, VI

时间窗: The individual participants are followed with annual assessments over a long time period (up to 30 years) or until discontinuation or death.

The Unified Parkinson's Disease Rating Scale (UPDRS) is the major rating scale used to assess severity of symptoms of Parkinson's disease, some of which are similar to symptoms in NBIA. The UPDRS subscales used in this study are Part I: Mentation, Behavior and Mood, scored from 0 (best) to 16 (worst); Part II: Activities of Daily Living, scored from 0 (best) to 52 (worst); Part III: Motor Examination, scored from 0 (best) to 108 (worst); and Part VI: Schwab and England Activities of Daily Living Scale, scored from 0% (worst) to 100% (best).

Disease progression

时间窗: The individual participants are followed with annual assessments over a long time period (up to 30 years) or until discontinuation or death.

Disease progression as assessed by clinical examination and captured as HPO (Human Phenotype Ontology) Terms at each visit.

Change in Score on Pediatric Quality of Life (PedsQL)

时间窗: The individual participants are followed with annual assessments over a long time period (up to 30 years) or until discontinuation or death.

The Pediatric Quality of Life (PedsQL) questionnaire is used to measure functional health and well-being from the patient's point of view. Separate versions of the questionnaire are available for children, young adults aged 18-25 years, and adults older than 25 years. Patients are asked to indicate how they have felt over the past month, and the scores of the 23 questions are used to generate an overall score that ranges from 0 (worst) to 100 (best).

次要结局

未报告次要终点

研究者

发起方
LMU Klinikum
申办方类型
Other
责任方
Principal Investigator
主要研究者

Prof. Thomas Klopstock

Prof. Dr. med.

LMU Klinikum

研究点 (9)

Loading locations...

相似试验

招募中
不适用
The International PNH Interest Group PNH RegistryParoxysmal Nocturnal Hemoglobinuria
NCT06524726International PNH Interest Group2,000
已完成
不适用
Developing a Nationwide Registry to Track Longitudinal Clinical Outcomes of Corneal Surgery and DiseaseCorneal DiseaseEndothelial Corneal DystrophyCorneal Transplant FailureCorneal Transplant Rejection
NCT06101017Nitin Vaswani19
尚未招募
不适用
National Database of the Virtual Institute of Cerebrovascular DiseasesCerebrovascular Disease
NCT05925699Fondazione Policlinico Universitario Agostino Gemelli IRCCS285,600
招募中
不适用
Natural History Study for Charcot Marie Tooth DiseaseCharcot-Marie-Tooth Disease Type 2ICharcot-Marie-Tooth Disease Type 2JCharcot-Marie-Tooth Disease Type 2ECharcot-Marie-Tooth Disease Type 2GCharcot-Marie-Tooth Disease Type 1CCharcot-Marie-Tooth Disease Type 2RCharcot-Marie-Tooth Disease Type 2O (Diagnosis)Charcot-Marie-Tooth Disease Type 2MCharcot-Marie-Tooth Disease Type 2PCharcot-Marie-Tooth Disease Type 2YCharcot-Marie-Tooth Disease Type 4F (Diagnosis)Charcot-Marie-Tooth Disease Type 4B3Charcot-Marie-Tooth Disease Type 2HCharcot-Marie-Tooth DiseaseCharcot-Marie-ToothCharcot-Marie-Tooth Disease, Type IACharcot-Marie-Tooth Disease Type 2ACharcot-Marie-Tooth Disease Type 2Charcot-Marie-Tooth Disease, Type 2CCharcot-Marie-Tooth Disease Type 2A2BCharcot-Marie-Tooth Disease Type 2B2Charcot-Marie-Tooth Disease Type 2A1Charcot-Marie-Tooth Disease Type 4B1Charcot-Marie-Tooth Disease, Type IBCharcot-Marie-Tooth Disease Type 2B1Charcot-Marie-Tooth Disease Type 2U (Diagnosis)Charcot-Marie-Tooth Disease Type 4ACharcot-Marie-Tooth Disease, Type 4A, Axonal FormCharcot-Marie-Tooth Disease Type 2A2ACharcot-Marie-Tooth Disease Type 2S (Disorder)Charcot-Marie-Tooth Disease and DeafnessCharcot-Marie-Tooth Disease Type 4B2Charcot-Marie-Tooth Disease Type 4HCharcot-Marie-Tooth Disease Type 1FCharcot-Marie-Tooth Disease Type 4CCharcot-Marie-Tooth Disease Type 4ECharcot-Marie-Tooth Disease Type 1DCharcot-Marie-Tooth Disease Type 2Q (Diagnosis)Charcot-Marie-Tooth Disease Type 2A2Charcot-Marie-Tooth Disease Type 2N (Diagnosis)Charcot-Marie-Tooth Disease Type 2B5Charcot-Marie-Tooth Disease Type 2DCharcot-Marie-Tooth Disease Type 4DCharcot-Marie-Tooth Disease Type 2KCharcot-Marie-Tooth Disease Type 2L (Diagnosis)Charcot-Marie-Tooth Disease Type 2TX-Linked Charcot-Marie-Tooth DiseaseHNPP
NCT05902351Hereditary Neuropathy Foundation10,000
招募中
不适用
National, Multicentric Registry Study on Neuroimmunological Diseases in ChinaNMO Spectrum DisorderMyelin Oligodendrocyte Glycoprotein Antibody-associated DiseaseMultiple SclerosisAutoimmune EncephalitisMyasthenia GravisAcute Disseminated Encephalomyelitis
NCT06443333Xuanwu Hospital, Beijing7,000